Emerging studies suggest Retatru tide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to provide a promising development for obesity treatment. Initial patient trials have shown considerable losses in body mass , potentially surpassing current obesity therapies . Nevertheless , more study is neede